Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.

CD40 is highly expressed on various B-lineage malignancies and represents an attractive immunotherapy target for neoplastic disease. Previous work showed that engineering the Fc domain of an antibody for increased binding to Fcγ receptors (FcγRs) significantly enhanced Fc-mediated immune effector function and antitumor activity in vitro and in vivo. We developed a humanized anti-CD40 antibody similarly Fc-engineered for increased FcγR binding (XmAbCD40) and compared its efficacy with that of an anti-CD40 native IgG1 analog and the anti-CD20 antibody rituximab. XmAbCD40 increased antibody-dependent cell-mediated cytotoxicity (ADCC) up to 150-fold relative to anti-CD40 IgG1 against B-lymphoma, leukemia, and multiple myeloma cell lines, and significantly enhanced ADCC against primary tumors. XmAbCD40 was also superior to rituximab in enhancing ADCC (both in cell lines and primary tumors) and in augmenting antibody-dependent cellular phagocytosis. XmAbCD40 significantly inhibited lymphoma growth in disseminated and established mouse xenografts and was more effective than the IgG1 analog or rituximab. An anti-CD40 antibody constructed to abrogate FcγR binding showed no reduction of tumor growth, indicating that the in vivo antitumor activity of XmAbCD40 is primarily mediated via FcγR-dependent mechanisms. These data demonstrate that XmAbCD40 displays potent antitumor efficacy and merits further evaluation for the treatment of CD40(+) malignancies.

[1]  G. A. Lazar,et al.  Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions , 2010, mAbs.

[2]  D. Ramies,et al.  Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Desjarlais,et al.  The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. , 2009, Blood.

[4]  N. Van Rooijen,et al.  Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40 , 2008, British Journal of Cancer.

[5]  R. Advani,et al.  A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma. , 2008 .

[6]  Holly M Horton,et al.  Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. , 2008, Cancer research.

[7]  Sang Hoon Lee,et al.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. , 2008, Blood.

[8]  J. Desjarlais,et al.  Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells , 2008, Molecular Cancer Therapeutics.

[9]  G. A. Lazar,et al.  Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. , 2007, Drug discovery today.

[10]  J. Stavenhagen,et al.  Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. , 2007, Cancer research.

[11]  G. A. Lazar,et al.  A molecular immunology approach to antibody humanization and functional optimization. , 2007, Molecular immunology.

[12]  P. Carter,et al.  Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. , 2007, Blood.

[13]  K. Kissler,et al.  Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primates , 2007, British journal of pharmacology.

[14]  S. Jagannath,et al.  A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma. , 2006 .

[15]  N. Munshi,et al.  Results of a Phase I Trial of SGN-40 (Anti-huCD40 mAb) in Patients with Relapsed Multiple Myeloma. , 2006 .

[16]  A. Baras,et al.  Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity , 2006, Springer Seminars in Immunopathology.

[17]  Wyne P. Lee,et al.  Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primates , 2006 .

[18]  V. Bedian,et al.  In vivo efficacy of the CD40 agonist antibody CP-870,893 against a broad range of tumor types: Impact of tumor CD40 expression, dendritic cells, and chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. A. Lazar,et al.  Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Brian J. Smith,et al.  Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. , 2005, Blood.

[21]  J. Collier,et al.  Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. , 2005, Cancer research.

[22]  G. Weiner,et al.  CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. , 2005, Journal of immunological methods.

[23]  N. Munshi,et al.  Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. , 2005, Cancer research.

[24]  L. Young,et al.  The role of the CD40 pathway in the pathogenesis and treatment of cancer. , 2004, Current opinion in pharmacology.

[25]  E. Kimby,et al.  Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  N. Munshi,et al.  Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. , 2004, Cancer research.

[27]  J. Vose.  Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. , 2004, The oncologist.

[28]  T. Robak.  Monoclonal Antibodies in the Treatment of Chronic Lymphoid Leukemias , 2004, Leukemia & lymphoma.

[29]  C. White,et al.  Antibody therapy of non-Hodgkin's B-cell lymphoma , 2003, Cancer Immunology, Immunotherapy.

[30]  P. Marlton,et al.  Incidence and nature of CD20‐negative relapses following rituximab therapy in aggressive B‐cell non‐Hodgkin's lymphoma: a retrospective review , 2002, British journal of haematology.

[31]  G. Botti,et al.  Cd40 Activation as Potential Tool in Malignant Neoplasms , 2002, Tumori.

[32]  D. Taub,et al.  Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. , 2002, Blood.

[33]  R. Offringa,et al.  CD40 stimulation leads to effective therapy of CD40− tumors through induction of strong systemic cytotoxic T lymphocyte immunity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[35]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[36]  Hua Yu,et al.  Anti-CD40 Antibody Induces Antitumor and Antimetastatic Effects: The Role of NK Cells1 , 2001, The Journal of Immunology.

[37]  M. Glennie,et al.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help , 1999, Nature Medicine.

[38]  M. Caligiuri,et al.  Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing , 1998, Cancer Immunology, Immunotherapy.

[39]  J. Banchereau,et al.  Functions of CD40 on B cells, dendritic cells and other cells. , 1997, Current opinion in immunology.

[40]  G. Freeman,et al.  Role of the CD40 and CD95 (APO‐1/Fas) antigens in the apoptosis of human B‐cell malignancies , 1997, British journal of haematology.

[41]  R. Bataille,et al.  Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. , 1994, Blood.

[42]  L. Lee,et al.  Monoclonal Antibodies in the Treatment of Non-Hodgkin’s Lymphoma , 1994, Clinical Immunotherapeutics.

[43]  D. Longo,et al.  Inhibition of human B-cell lymphoma growth by CD40 stimulation. , 1994, Blood.

[44]  I. Jónsdóttir,et al.  Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder , 1984, Cancer Immunology, Immunotherapy.

[45]  J. Castillo,et al.  Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. , 2009, Expert opinion on investigational drugs.

[46]  E. Sotomayor,et al.  Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. , 2007, Hematology. American Society of Hematology. Education Program.

[47]  K. Flaherty,et al.  Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[49]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[50]  L. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for Fc g RI, Fc g RII, Fc g RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc g R* , 2001 .

[51]  R. Flavell,et al.  CD40 and CD154 in cell-mediated immunity. , 1998, Annual review of immunology.

[52]  J. Banchereau,et al.  The CD40 antigen and its ligand. , 1994, Annual review of immunology.

[53]  S. Howie,et al.  CD40 expression in Hodgkin's disease. , 1994, The American journal of pathology.